Roche reported diagnostics revenues down 4% year‑to‑date and told investors that China's volume‑based procurement and diagnostic‑related group audits materially hit pricing and volumes in 2025. Management said it expects those headwinds to moderate in 2026 and confirmed ongoing investments in pathology and molecular diagnostics. The results highlight how regulatory and procurement reforms in China continue to reshape global diagnostics pricing and trade flows, forcing large vendors to reprice product mixes and adjust regional forecasts.